Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

AdaptHealth (AHCO) EBITDA (2018 - 2025)

AdaptHealth has reported EBITDA over the past 8 years, most recently at $19.2 million for Q4 2025.

  • Quarterly results put EBITDA at $19.2 million for Q4 2025, down 89.48% from a year ago — trailing twelve months through Dec 2025 was $452.4 million (down 25.45% YoY), and the annual figure for FY2025 was $452.5 million, down 25.44%.
  • EBITDA for Q4 2025 was $19.2 million at AdaptHealth, down from $154.3 million in the prior quarter.
  • Over the last five years, EBITDA for AHCO hit a ceiling of $182.7 million in Q4 2024 and a floor of -$370.7 million in Q3 2023.
  • Median EBITDA over the past 5 years was $131.3 million (2021), compared with a mean of $87.5 million.
  • Biggest five-year swings in EBITDA: skyrocketed 921.27% in 2021 and later plummeted 373.91% in 2023.
  • AdaptHealth's EBITDA stood at $134.1 million in 2021, then decreased by 11.22% to $119.0 million in 2022, then plummeted by 210.06% to -$131.0 million in 2023, then surged by 239.44% to $182.7 million in 2024, then plummeted by 89.48% to $19.2 million in 2025.
  • The last three reported values for EBITDA were $19.2 million (Q4 2025), $154.3 million (Q3 2025), and $166.5 million (Q2 2025) per Business Quant data.